sar425899 sanofi dual glp-1 glucagon agonist Clinical relevance of dual agonist of glucagon and glucagon Multiagonists Currently in Development. |
Description
Diabetes Ther Res Treat Educ Diabetes Rel Disorders
On the biological side, companies are developing ways to better incorporate ncAAs peptides recombinantly (e.g., Constructive Bio) or optimizing cell-free expression systems to rival the cost-efficiency / scale of cell-based systems (e.g., Isomerase)
1 (2019): 107, 10.2991/jegh.k.191028.001
doi: 10.1161/HYPERTENSIONAHA.114.03062
